TOKYO, May 25 (Pulse News Wire) – Renascience Inc. (4889.T) announced today that its board of directors decided to reduce the capital reserve fund and dispose surplus funds at the upcoming 27th regular shareholders' meeting scheduled for June 25, 2026.
As of March 31, 2026, the company held a capital reserve fund amounting to ¥2.403 billion and recorded a deficit of ¥1.136 billion in carried-forward profit surplus. To address this, the company plans to decrease the capital reserve fund by ¥1.136 billion and reallocate it to other capital surplus reserves. Additionally, pursuant to the Companies Act, the company intends to transfer ¥1.136 billion from the increased other capital surplus reserves to the carried-forward profit surplus to cover the deficit.
This adjustment will not affect the number of shares owned by shareholders nor alter the total issued share count. Consequently, there will be no changes to the per-share net assets value. Following the adjustments, the company's balance sheet will reflect: - Shareholders' equity: ¥3.310 billion - Paid-in capital: ¥1.982 billion - Other capital surplus: ¥61.2 million - Carried-forward loss surplus: Reduced to zero Key milestones for the process include: - Board resolution date: May 25, 2026 - Scheduled shareholder meeting date: June 25, 2026 - Notice publication date for creditor objections: June 26, 2026 - Final deadline for creditor objections: July 31, 2026 - Effective date: August 7, 2026 The company expects no impact on performance metrics as these actions involve internal account transfers within shareholders' equity without altering the overall net asset value.
Approval at the shareholders' meeting remains conditional.
🟢 Confidence: High AI-translated content.